Last reviewed · How we verify

NCT06980818: MIBD

Oral Microbiota Dysbiosis in IBD

Active, enrolled Last updated 20 May 2025
What this trial tests

trial testing No intervention in Inflammatory Bowel Disease (IBD) in 130 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
11 March 2022
Primary endpoint
30 November 2025
31 December 2025

Quick facts

Lead sponsorULS Viseu Dão Lafões
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment130
Start date11 March 2022
Primary completion30 November 2025
Estimated completion31 December 2025
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

ULS Viseu Dão Lafões

Who can join

18 and older, any sex, with Inflammatory Bowel Disease (IBD) or Dysbiosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to provide new insights into oral microbiota dysbiosis and IBD. Given the strong association between oral health, microbiome composition, and IBD, all participants will undergo an oral evaluation program conducted by dentists from the Faculty of Dentistry at Universidade Católica Portuguesa (UCP). This program will facilitate the characterization of oral health and its correlation with IBD status.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Inflammatory Bowel Disease (IBD)

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06980818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing